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In this article, we give an update on recent findings regarding molecular pathology in cuta-
neous melanocytic tumors. The focus lies on use of genetics in the diagnosis of distinct
subtypes of spitzoid tumors that are often characterized by specific phenotypic–genotypic
alterations that can frequently be recognized by adequate histological examination. Typ-
ical illustrating cases are given in order to increase recognition of these lesions in daily
dermatopathology practice. New molecular findings in the pathogenesis of congenital
melanocytic tumors and neurocutaneous melanosis are reviewed. In addition, use of muta-
tion analysis in the differential diagnosis of melanoma metastasis is discussed. Finally,
application of mutation analysis in targeted therapy in advanced melanoma with advantages
of new techniques such as next generation sequencing is described.
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INTRODUCTION
During the past 20 years, there has been a rapid development of
molecular techniques increasing the possibilities of genetic test-
ing in all kinds of tumors including melanocytic tumors. This
has led to a rapid gain in our knowledge on the development of
melanocytic tumors, which can help in diagnosis, prognosis, and
treatment of melanocytic tumors. In 2010, we wrote a review on
the molecular pathology of these tumors (1). Since developments
in the field are fast, we will address in this paper relevant new find-
ings from the recent years within the field of molecular pathology
in melanocytic lesions.
The first part has a focus on new findings with respect to
diagnosis and pathogenesis. The focus will be on new molecular
findings in spitzoid tumors, in congenital melanocytic nevi (CMN)
and neurocutaneous melanocytosis, and the use of molecular tests
in the (differential) diagnosis of melanoma.
The second part will will be devoted to application of mole-
cular pathology in the treatment of melanoma, and will briefly
address new technological developments such as next generation
sequencing (NGS) techniques in this setting.
PART 1: MOLECULAR PATHOLOGY IN THE DIAGNOSIS AND
PATHOGENESIS OF MELANOCYTIC TUMORS
Early events in the development of melanocytic tumors are often
hotspot mutations in genes involved in the MAPK pathway, which
is one of the most important pathways involved in melanocytic
tumor development (Figure 1). Important oncogenes in this path-
way are BRAF (7q34), NRAS (1p13), HRAS (11p15), GNAQ
(9p21),GNA11 (19p13), andKIT (4q12) (2–5). Mutations in these
genes are mostly mutually exclusive, by themselves do not cause
malignant progression, stay present with malignant progression,
and activate the MAPK pathway. Different subtypes of benign
and malignant melanocytic tumors are characterized by different
mutations in these genes of the MAPK pathway.
In common nevi for instance, BRAF and NRAS mutations are
present in 60–87.5% (6, 7) and 20%, respectively. In large congen-
ital nevi upto 80%, NRAS mutations are reported (7, 8). In blue
nevi, mainly GNAQ (83%) and GNA11 (7%) mutations are found
(9), and in Spitz nevi, HRAS mutations are reported in 20–29%
(7, 10).
Especially, in Spitz tumors, several new data indicate that these
tumors are genetically more diverse than was previously thought.
We will discuss these new findings below in part 1, together with
new insights in the pathogenesis of CMN and the rare disease of
neurocutaneous melanocytosis. We will also address the role of
molecular pathology in the differential diagnosis of (metastatic)
melanoma.
The distinct mutations in different melanoma types will be
discussed later in part 2 (see also Table 1).
WHAT IS NEW IN SPITZOID MELANOCYTIC TUMORS?
At present, roughly three subgroups of spitzoid melanocytic
tumors can be identified based on distinct genetic alterations.
The first one is the group of the HRAS-mutated spitzoid tumors
(13). The second group is the one of the BAP1-mutated “spitzoid
lesions” (14, 15), and the third group consists of spitzoid tumors
with kinase fusion (16).
The first two groups seem to be characterized mostly by a typ-
ical phenotype that can be recognized or at least suspected upon
histological evaluation.
Most of the HRAS-mutated spitzoid tumors are typically
wedge shaped, dermal-based lesions, with an infiltrative margin,
consisting of mostly spindle-shaped cells, and showing marked
desmoplasia (13, 17). This group is relevant to discriminate
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because of the favorable prognosis and to prevent melanoma
overdiagnosis.
Several studies have reported the presence of HRAS mutations
in spitzoid tumors with benign behavior, and absence in clear-cut
spitzoid melanomas (10, 17, 18). There is only one recent paper
mentioning the occurrence of HRAS mutations in upto 10% (2/20
cases examined) of primary cutaneous melanomas (19). In this
paper, no histology of the lesions is shown or described; therefore,
FIGURE 1 |Two important pathways involved in the development of
melanocytic tumors and melanoma: the MAPK pathway and the
AKT/PI3K-pathway. Activation of both routes leads to proliferation. NRAS
plays an important role in both pathways. Mutations in GNAQ, GNA11, and
BRAF lead to activation of the MAPK pathway only, while mutations in KIT
and NRAS can activate both pathways. Different inhibitors can be applied in
targeted therapy of advanced melanoma patients, and their points of action
are indicated also. MEK inhibitors can be effective in case of several
different gene mutations in the MAPK pathway, because they exert their
effect in the distal part of the pathway.
whether these lesions were spitzoid or not remains unclear, and
no follow-up data of the patients are included to confirm the pro-
posed diagnosis of melanoma by the authors. Furthermore, this
paper also gives mutation frequencies of BRAF (25%) and NRAS
(10%) that are quite different from most studies in the melanoma
field.
In 2010, we described a series of 24 HRAS-mutated spitzoid
melanocytic tumors (13). In 7/24 (29%) of these lesions, the initial
diagnosis or important differential diagnosis had been melanoma
based upon histological examination alone. These were mainly
cases in adults that displayed rather frequent or deep mitotic activ-
ity. In five cases, more than 2 mitoses/1 mm2 or deep mitoses
were present. In this series with a mean and median follow-up of
10.5 years, no recurrences or metastases occurred. An example of
a HRAS-mutated spitzoid lesion is depicted in Figure 2.
The second group, which we preferentially call MBAITs
(melanocytic BAP1-associated intradermal tumors, but are also
called Wiesner tumor or BAPoma) are often polypoid, dermal
based, consisting of large epitheloid “spitzoid-looking” cells, that
can have a small common nevus component at the margin (espe-
cially in BAP1-germline mutated lesions), and in one-third of
cases, there are prominent tumor-infiltrating lymphocytes (TILs).
These BAP1-mutated melanocytic lesions were first described
by Wiesner et al. They described two families, one in Australia and
one in Germany, in which a total of 16 individuals were affected by
atypical cutaneous melanocytic tumors, in association with cuta-
neous and uvea melanomas (14). The affected family members
were found to have a BAP1-germline mutation. Subsequently, it
was found that these spitzoid-looking MBAITs, besides a BAP1
mutation, also contained a BRAF mutation. Later, these lesions
were also described in a sporadic setting in so-called atypical spit-
zoid tumors (ASTs), without having an underlyingBAP1-germline
mutation (15, 20). In 2012, Wiesner et al. described a series of
32 ASTs (20). Nine cases (28%) showed BAP 1 protein expres-
sion loss while BRAF protein expression was present. In 8/9 cases
(89%), a BRAFV600E mutation was found, and in 5/9 cases (55%),
a somatic BAP1 mutation was present. No HRAS mutations were
Table 1 | Overview of frequencies of gene mutations in different melanoma subtypes derived from different locations.
Localization primary melanoma BRAF NRAS KIT GNAQ GNA11
7q34 1p13.2 4q12 9p21 19p13
Melanoma from CSDS/LMM 8% 15% 28% 1.4% 0
Melanoma from NCSD skin 60% 22% 0%-very low 0 0
ALM 22% 10% 23–36% 0 0
Mucosal melanoma 3–11% 5–24% 16–39% 0 0
Uvea melanoma 0% 0% 0% 45–50% 32%
Melanoma from the CNS 0% 0-low in adults. Frequently
mutated in melanoma in
context of NCM in children.
0% 30% (adults) 30% (adults)
Sensitive to treatment with BRAF
inhibitors
MEK inhibitors. Resistant to
BRAFi
Imatinib, nilotinib,
sunitinib, dasatinib
(Pre-clinical) MEK
inhibitors
(Pre-clinical) MEK
inhibitors
In different studies, there is some variation in reported frequencies (5, 11, 12).
CSDS, chronic sun damaged skin; LLM, lentigo malignant melanoma; ALM, acrolentiginous melanoma; CNS, central nervous system.
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FIGURE 2 | HRAS-mutated spitzoid tumor in a female patient aged
47 years. The lesion was located on the right lower arm and measured 0.8 cm
in diameter. The lesion was diagnosed elsewhere as STUMP (Spitzoid tumor
of uncertain malignant potential). (A,B) The lesion was symmetrical, wedge
shaped, mainly dermal located, with epithelioid spitzoid-looking cells in an
eosinophilic hyalinized stroma [(A) HE 25×, (B) HE 400×]. There were 2
mitoses present per 1 mm2. Deep mitoses were absent. (C) Sequence plot of
the mutation HRAS c.182A>T(p.(Gln61Leu)) with 44% of mutant alleles. The
genomic sequence of the gene investigated is marked in green bars, and the
protein sequence information is on top of the gene sequence. The combined
(forward and reverse) gene sequence information is highlighted in light green,
and the expected protein sequence is placed on top. The forward sequence
information is indicated as light blue bars and reverse sequence information
as purple bars. The square box shows the number and percentage of the
different nucleotides at the variant position; the red vertical bar indicates the
HRAS hotspot mutation position. The sequence plots are generated in
SeqNext (from JSI Medical Systems GmbH). Note that the HRAS RefSeq is
NM_005343.2.
found. Histology was comparable to the BAP1-germline mutation
associated MBAITs, demonstrating a dermal-based lesion, plump
epithelioid cells, giant cells, with in 1/3 cases prominent TILs, and
absence of prominent fibrosis. These cases were not described to
contain a small nevoid component in contrast to the germline
BAP1-associated cases.
Yeh et al. recently described genomic loss, determined with
array CGH, of >1 Mbp of chromosome 3 in a region contain-
ing the BAP1 locus in a series of 29 cases out of 436 ambiguous
melanocytic tumors (6.7%) (21): 22 cases showed partial loss of
chromosome 3, while 7 cases demonstrated monosomy of chro-
mosome 3. In 11 casesBAP1mutation analysis was performed with
in 10 cases a loss of function mutation of BAP1, and in the remain-
ing single case with wild-type BAP1, BAP1 protein expression was
lost on the immunohistochemical level. In the cases with loss of
1 copy of BAP1, the BAP1 protein expression was always lost. So,
immunohistochemistry for BAP1 protein seems to correlate well
with the genetic findings. Reported follow-up in their series was
good, although short (median 17 months), with no recurrences,
and in one patient a negative sentinel lymph node. Morphology
of 17 lesions with biallelic loss of BAP1 that looked spitzoid was as
described previously by others, with TILs being present in 50% of
cases, and 31% having a small nevoid component at the margin. In
these cases, a junctional component was present composed of the
common nevus component. In one case without a common nevus
component, a junctional spitzoid component was present. In 12/17
cases, a BRAFV600E mutation was present, 4 cases were wildtype
BRAF, and 1 case showed an NRASQ61R mutation. The latter is
rarely reported at present, but we have also encountered such a case
ourselves recently (paper submitted). In our patient, no underly-
ingBAP1mutation was found. The other reportedNRAS-mutated
case (21) in literature was not tested for a germline mutation in
BAP1. Most of the MBAIT cases reported thus far do not seem to
be tested for the presence of NRAS mutations, so the number of
NRAS-mutated cases may be larger, and the genetic make-up of
these BAP1-associated melanocytic lesions could be broader than
currently thought.
The fact that the combined MBAIT lesions show onlyBAP1 loss
in the epithelioid component suggests that they probably develop
from a common nevus (that is mostly BRAF and seldom NRAS
mutated) (7).
MBAITs probably have a low risk of developing into melanoma,
but at present, data about behavior are insufficient to draw definite
conclusions.
In the two largest series thus far by Pouryazdanparast et al.
(22) and Yeh et al. (21), reporting 28 and 29 cases, respectively,
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follow-up was favorable without recurrences. Follow-up was rela-
tively short with a mean of 21 months and median of 17 months,
respectively. Pouryazdanparast performed FISH [using probes tar-
geting chromosome 6p25 (RREB1), chromosome 6q23 (MYB),
chromosome 11q13 (CCND1), and the centromeric portion of
chromosome 6 (CEP 6)] on these lesions, which was negative in
all cases.
The difference in outcome between the uveal lesions and the
skin lesions with aBAP1mutation may be related to the presence of
different oncogenic driver mutations in uveal lesions, which har-
bor GNAQ or GNA11 mutations (23) instead of BRAF or NRAS
mutations.
The suggested progression-promoting effect of mutated BAP1
is in line with the tumor suppressive function of intact BAP1 as
a deubiquitylase required for efficient assembly of the homol-
ogous recombination (HR) factors BRCA1 and RAD51 after
DNA double-strand breaks (DSBs) (24, 25). BAP1 is recruited to
DNA damage sites together with ASXL1 and deubiquitilates Ub-
H2AK119 at sites of DNA damage (24, 25). In this way, it promotes
error-free repair of these lesions. Defective HR and increased sen-
sitivity to radiation due to BAP1 deficiency may, therefore, lead
to genomic instability, a hallmark of cancer (24, 25). Moreover,
BAP1 prevents proteasomal degradation of the conserved epige-
netic regulator host cell factor-1 (HCF-1) and, consistent with
this, Dey et al. showed that BAP1 KO splenocytes contained far
less HCF-1 than their wild-type counterparts (26). It is thought
that BAP1 regulates gene expression via stabilization of HCF-1
(26). These two examined functions of BAP1 could explain tumor
progression due to altered BAP1 expression.
The most important reason for recognition of MBAITs at
present is that they can be a marker of an underlying BAP1-
associated germline mutation/cancer syndrome. Individuals with
a BAP1-germline mutation have an increased risk to develop cuta-
neous and ocular melanoma and mesothelioma, apart from the
risk to develop multiple MBAITs (27).
Management of MBAIT lesions should consist of complete
removal of the lesion and advise for genetic counseling to exclude
a potential underlying cancer syndrome.
TypicalBRAF-mutated MBAIT cases from our own practice are
shown in Figures 3 and 4 (Courtesy Dr. R. Kornegoor, Department
of Pathology, Gelre Hospitals, Apeldoorn, The Netherlands).
In case of suspicion of a MBAIT lesion, we recommend at least a
BRAF and BAP1 immunostaining, but preferentiallyBRAF,NRAS,
HRAS, and BAP1 mutation analysis is performed. In case a labora-
tory cannot perform these, we recommend consultation because
of the important implications of a correct diagnosis. Mutation
analysis of the BAP1 gene is difficult, since it is a complex gene and
mutations can be present along all of the 17 exons of the gene. A
low tumor percentage due to the small size of a lesion or small size
of the spitzoid component, or the presence of a lot of TILs, can all
hamper BAP1 mutation analysis in this setting.
The third group of spitzoid lesions, those with kinase fusions
has only recently been described. Wiesner et al. described the pres-
ence of alterations in ROS1, NTRK1, ALK, BRAF, and RET in,
respectively, 17%, 16%, 10%, 5%, and 3% of spitzoid tumors.
These alterations were present along the entire spectrum of the
spitzoid tumors (55% in Spitz nevi, 56% in AST, and 39% in spit-
zoid melanoma), and these alterations therefore seem early events,
and are not useful (yet) for differentiating benign from malignant
spitzoid lesions. No clear distinct phenotypes were described at
this time.
Recently, Busam et al. described 17 cases of Spitz tumors with
ALK fusion, including 5 Spitz nevi and 12 AST (28). Clinically,
these lesions were often polypoid. Histology showed a compound,
mostly dermal located lesions with a plexiform growth, and con-
sisting of fusiform melanocytes. In only 2 cases, the lesional cells
contained pigment.
All cases showed ALK protein expression. ALK FISH was posi-
tive in all cases (using a commercially available break-apart probe,
Abbott Molecular, Des Plaines, IL): in 11/17 cases, the fusion part-
ner was tropomyosin 3 (TPM-3), in 6/17 cases, the fusion partner
was dynactin 1 (DCTN-1). FISH for copy number alterations did
not meet the criteria for melanoma diagnosis in any case. Array
CGH revealed no chromosomal gains or losses. In 2 cases, a sen-
tinel node procedure was performed and in both cases showed
small nests in the subcapsular sinus. Both patients were alive and
well after <1 year and after 4 years of follow-up. At present, the
follow-up time and number of cases is too limited to draw definite
conclusions about the prognosis of this group of Spitz tumors with
ALK fusions.
An ALK-positive Spitz tumor is presented in Figure 5 (Courtesy
Prof. Dr. J. van den Oord, KU Leuven, Belgium).
The anaplastic lymphoma kinase (ALK) gene, located on chro-
mosome 2p23, is a receptor tyrosinase kinase protein and is capable
of causing diverse tumor types of different lineages through a vari-
ety of molecular mechanisms (29). The most common mechanism
of ALK activation is a genomic rearrangement involving the ALK
locus, with a breakpoint in the 3′ end of the ALK gene, with the
other breakpoint involving a diverse group of genes leading to for-
mation of a fusion oncogene that encodes for a fusion oncoprotein
that is able to self-associate (29). Another way of ALK activation
is by gain-of-function point mutations, but these are less frequent
than ALK rearrangements. Also, ALK amplifications have been
described in several tumor types, leading to the presence of multi-
ple copies of the wild-type full-length ALK gene. But the way this
contributes to tumor development is poorly understood (29).
As mentioned above, in spitzoid tumors at present, only ALK
rearrangements have been tested and described, and present in
upto 19% of cases (16), with TPM-3 and DCTN-1 as fusion part-
ners (16, 28). ALK rearrangements leading to TPM3-ALK fusion
have also been reported in anaplastic large cell lymphoma and
papillary thyroid carcinoma, and result in a constitutive tyrosinase
kinase activity, in this way causing tumor development (29).
Relevance of diagnosis of Spitz tumors with kinase fusions at
the moment is mainly for treatment in malignant lesions (e.g.,
ALK,RET,ROS 1 alterations can be targeted with kinase inhibitors,
such as crizotinib, cabozantinib, and vandetanib).
Table 2 summarizes the characteristic features of the three
above-described subtypes of spitzoid melanocytic lesions, includ-
ing the most common histological findings, and genetic and
prognostic features, with clinical relevance of recognition of these
subtypes.
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FIGURE 3 | BRAF-mutated MBAIT in a 31-year-old female located on the
lower back (Courtesy Dr. R. Kornegoor, Gelre Hospitals, Apeldoorn,The
Netherlands). (A) Overview (HE 25×), showing a polypoid lesion above the
skin surface. The central part (B) (HE 400×) consists of large epithelioid cells
with intermingled lymphocytes. The margin (C) (HE 100×) shows a common
compound nevus. (D) Molecular analysis showed a BRAFV600E mutation. In
(D), sequence plot of the mutation BRAF c.1799_1800TG>AA (p.(Val600Glu)
alias p.V600E) with 7% mutant allel (very low load). Note that the BRAF
RefSeq is NM_004333.4. The sequence plots are visualized as described
under Figure 2. Immunohistochemistry demonstrated positive BRAF protein
expression, and loss of BAP1 protein expression in the large epithelioid cells
(not shown).
MOLECULAR BACKGROUND OF CONGENITAL MELANOCYTIC NEVI
(CMN) AND NEUROCUTANEOUS MELANOSIS (NCM)
Congenital melanocytic nevi are pigmented moles present at birth
or shortly thereafter (30). They vary in size from small to very large
or“giant”and hundreds of CMN can be present in one patient (31).
CMN are considered to be a sporadic event with the exception of a
few familial cases (32, 33). Especially giant CMN (>40 cm in size)
are associated with an increased risk for cutaneous melanoma (up
to 10–15% life-time risk) (34).
Both NRAS and BRAF mutations have been detected in CMN
in a mutually exclusive pattern, and there is a genotype–phenotype
correlation between the size of CMN and type of mutation.
Especially, large and giant CMN harbor somatic NRAS muta-
tions (>75%) in contrast to medium-sized CMN that are less
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FIGURE 4 | BRAF -mutated MBAIT lesion located on the posterior
side of the ear in a 55-year-old female (Courtesy Dr. R. Kornegoor,
Gelre Hospitals, Apeldoorn,The Netherlands). In (A), an overview
showing a nodular dermal-based lesion with lymphocytes at the lateral
margin. In this case, no common nevus component was present (HE,
25×). (B) A higher magnification demonstrates the large epithelioid
aspect of the cells (HE, 200×). In (C), absence of BAP1 protein
expression is seen in the large epithelioid melanocytes. Nuclei in the
keratinocytes in the epidermis stain positive, serving as a positive
internal control (400×). In (D), BRAF protein is expressed by the large
epithelioid melanocytes (400×). (E) Sequence plots of the mutation
BRAF c.1799T>A (p.(Val600Glu) alias p.V600E) with 23% mutant alleles
and of the BAP1 (RefSeq NM_004656.2) c.581-1G>A splice site
mutation with 34% mutant alleles. The sequence plots are visualized as
described under Figure 2. In the BAP1 plot, the intron–exon boundary is
represented as gray-white parts.
frequentlyNRAS mutated and especially small CMN and acquired
melanocytic nevi that frequently carry BRAFV600E mutations (up
to 80% in acquired nevi) (35). Activating BRAFV600E mutations
in large CMN are rare (approximately 15%) (6). A few cases
of large CMN were shown to harbor a chromosomal transloca-
tion involving BRAF resulting in gain-of-function, and this could
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FIGURE 5 | ALK-positive spitzoid tumor diagnosed as spitzoid
tumor of uncertain malignant potential (STUMP). This lesion was
seen in consultation elsewhere (Courtesy Prof. Dr. J. van den Oord, KU
Leuven, Belgium). The lesion was clinically polypoid and presented on
the arm of a 4-year-old girl. There were 11 mitoses/1 mm2 present.
Follow-up data are not available yet. In (A), HE overview (25×); in
(B,C), larger magnification (HE 200–400×, respectively) showing
spindle-shaped cells and some lymphocytes intermingled; (D) PHH3
staining demonstrating mitoses (400×); (E) mitf (250×); and (F) ALK
(250×).
represent an alternative mechanism of BRAF activation in BRAF-
or NRAS-wild-type CMN (36).
Recently, using several highly sensitive techniques, Charbel et al.
showed that large and giant CMN contain NRASQ61 mutations
(Q61R or Q61K) in up to 94.7% of cases (37). In addition, using
whole-exome sequencing, they found no other coding mutations
in five large/giant CMN implying that at present NRAS mutations
are the sole recurrent mutation in these lesions. Somatic NRAS
mutations, therefore, seem to be sufficient to drive melanocytic
proliferations in utero. In addition, identical NRASQ61 mutations
were recently demonstrated in multiple CMN samples from the
same patient (38). This finding suggests that multiple CMN are
clonal proliferations caused by a single, postzygotic NRAS muta-
tion in a neuro-ectodermal precursor cell rather than de novo
proliferations arising from different mutations.
Kinsler et al. recently proposed the term “CMN syndrome” as
they observed that patients with CMN often have characteristic
facial features (such as wide or prominent forehead and appar-
ent hypertelorism) (39). The osteocartilageneous structures of
the face are neuro-ectodermal in origin and can be affected by
mutations in components of the RAS/RAF/MEK/ERK pathway in
patients with germline RASopathies who have characteristic facial
features (40). Kinsler et al. hypothesized that the occurrence of a
postzygotic, somatic NRAS mutation in early neuro-ectodermal
precursors might be responsible for the characteristic facial fea-
tures in patients with CMN as well (38). In addition, as they
observed a high prevalence of red hair in families of children with
CMN, a germline predisposition for the development of the“CMN
syndrome” was hypothesized. Indeed, they showed that certain
germline allele variants of the melanocortin-1-receptor (MC1R),
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Table 2 | Subtypes of spitzoid melanocytic tumors with their phenotypical and genotypical characteristics, and relevance of diagnosis.
Subtypes spitzoid
melanocytic tumors
HRAS-mutated
spitzoid tumors
BAP 1-mutated spitzoid tumors (MBAIT) Spitzoid tumors with kinase fusions
Histological
characteristics
(phenotype)
Dermal-based lesions Mostly dermal based No distinct phenotypes identified yet.
Wedge shaped Often polypoid
Desmoplasia Often TILs
Often spindle-shaped
cells
Epithelioid cells, a common nevus component
can be present.
ST with ALK fusions recently reported as often
polypoid with plexiform growth of fusiform
melanocytes (28).
Genetic alterations HRAS mutations or
amplification
BAP1 mutation Specific fusion of certain genes (ROS1 17%,
NTRK1 16%, ALK 10%, BRAF 5%, RET 3%).Often with combined BRAFV600E mutation. Rare
cases with combined NRAS mutation reported
Single 11p gain can be
present.
Loss of (a part of) chromosome 3 can be
present.
In ALK-used STs, no chromosomal gains or
losses reported thus far (28).
Relevance of diagnosis Favorable prognosis
(prevention of
overdiagnosis of
melanoma).
Can be a marker of a BAP1 cancer syndrome.
Genetic counseling should be advised.
In case of malignant/metastatic cases targeted
treatment is an option (ALK, ROS, and RET
alterations can be targeted by kinase inhibitors
like crizotinib, cabozantinib, and vandetanib).
Behavior not clear yet. Behavior not clear yet.
TILs, tumor-infiltrating lymphocytes; ST, Spitz tumor; MBAIT, melanocytic BAP1-associated intradermal tumor.
known to be responsible for the red hair/fair skin/freckling phe-
notype, are associated with the presence of CMN (as well as with
more extensive CMN) (41).
Congenital melanocytic nevi can be associated with a spec-
trum of neurological abnormalities, including malformations (for
instance, Dandy–Walker malformation), communicating hydro-
cephalus, arachnoid cysts, CNS tumors (for instance, astrocytoma
and choroid plexus papilloma) and also melanotic abnormali-
ties (38). The latter is called neurocutaneous melanosis (NCM)
and refers to the presence of large of multiple CMN in associ-
ation with melanin depositions in the brain parenchym (visible
on T1-weighted MRI) or melanocytic tumors like leptomeningeal
melanocytosis or melanoma (42). Leptomeningeal melanocytosis
consists of a diffuse proliferation of histological benign appear-
ing melanocytes in the leptomeninges, without CNS invasion, and
carries a poor prognosis once symptomatic (42).
Recently, it was shown that postzygotic, somatic NRAS muta-
tions contribute to the pathogenesis of NCM. Identical, somatic
NRASQ61 mutations were detected in multiple CMN as well
as in the CNS melanocytic tumor in the same NCM patients
(43). Kinsler et al. also detected a somatic NRASQ61 mutation
in three non-melanocytic CNS tumors occurring in patients with
CMN (including choroid plexus papilloma, neurocristic hamar-
toma, and meningioma) (38). The presence of identical, somatic
NRASQ61 mutations in both CMN and in CNS melanocytic (and
non-melanocytic) neoplasms in the same patients suggests that
these mutations occur in the developing neuro-ectoderm early
during embryogenesis. In fact, this pathogenetic mechanism fits
the spectrum of mosaic RASopathies that are characterized by
postzygotic mutations resulting in the presence of at least two
genetically distinct cell populations in the same organism (44). For
instance, postzygotic, somaticRAS mutations (HRAS,KRAS) were
recently shown to be present in distinct lesions of the keratinocytic
epidermal nevus syndrome, a mosaic RASopathy characterized by
the presence of epidermal nevi in association with extra-cutaneous
abnormalities (CNS, ocular, skeletal, cardiovascular, and geni-
tourinary system) (44). The phenotype in the spectrum of mosaic
RASopathies is most likely determined by type of mutation, the
timing of the mutation, and affected cell type (44, 45).
A mouse model has demonstrated a role for postzygotic, early
embryonicNRAS mutations in the pathogenesis of NCM. By using
the Cre-loxP technology, Pedersen et al. showed that expression of
oncogenic NRASG12D in melanocytes early during embryogene-
sis resulted in a mouse phenotype strongly resembling NCM in
human beings (43) As NRAS mutations occur in benign lesions
such as CMN, they are in itself insufficient for malignant transfor-
mation of melanocytes, and better insight in the genetic aberra-
tions eventually leading to melanoma is needed. NRAS mutations
are a therapeutic target for treatment with MEK inhibitors. In a
Phase II trial, treatment with MEK162 was shown to have effect
in some patients with advanced NRAS-mutated melanoma and a
Phase III trial is ongoing (46). For patients with NRAS-mutated
CNS melanocytic tumors, treatment with MEK162 might be of
benefit as well (47).
MOLECULAR DIAGNOSTICS IN THE DIFFERENTIAL DIAGNOSIS OF
MELANOMA (METASTASIS)
Melanomas are known for their wide range of cytomorphologic
features and architectural patterns and may mimic various non-
melanocytic tumors [reviewed by Banerjee et al. (48, 49)]. In most
cases, a diagnosis can be rendered by careful examination of the
histomorphology and by sometimes adding immunohistochem-
ical stains. In some cases, however, especially in recurrences and
metastases, melanomas can show an aberrant immunophenotype
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with loss of lineage-specific markers. In part of these cases, mol-
ecular analysis of genes in the MAPK pathway and CDKN2A (7)
mutation analysis can be useful in the differential diagnosis. In
addition, molecular analysis can be of help in determining the site
of the primary melanoma in case of metastasis with an unknown
primary since melanomas from different locations have different
mutation types (see Table 1). Furthermore, molecular analysis can
help to discriminate between a melanoma metastasis and a second
primary melanoma.
One of the lesions that can be hard to distinguish from
melanoma is clear cell sarcoma (CCS) as they share histopatholog-
ical features and cannot be distinguished by immunohistochem-
istry (50). Classically, CCS is a deep soft tissue tumor associated
with tendons and aponeuroses (51), but it can also present as
a cutaneous lesion (52), and then has to be differentiated from
metastatic or primary nodular melanoma. While most cutaneous
melanomas harbor a BRAF or NRAS mutation (see Table 1), CCS
in approximately 75% have a t(12;22)(a13;q12) or less commonly
a t(2;22)(q34;q12) translocation leading to the EWSR1/ATF1 or
EWSR1/CREB1 fusion transcripts (53, 54). Yang et al. (55) per-
formed BRAF and NRAS mutation analysis, as well as FISH
analysis for the EWST1/ATF1 fusion gene in 31 melanoma cases
and 16 CCSs. They found the translocation in 78.6% of the
CCSs but in none of the melanomas, whereas BRAF and NRAS
mutations were present in, respectively, 51.6 and 12.9% of the
melanomas and not in any of the CCSs. Hantschke et al. (52)
described 12 cases of cutaneous CCS in which FISH analysis for
the t(12;22)(a13;q12) translocation contributed in the differential
diagnosis with melanoma. This implicates that this type of analysis
can be of great aid in the differential diagnosis between CCS and
melanoma.
Recently, we described two cases in which mutation analy-
sis lead to the correct diagnosis of (dedifferentiated) metastatic
melanoma (56). Both patients had a history of melanoma and
presented several years after their primary diagnosis with a lesion
histologically and immunohistochemically different from the pri-
mary melanoma and mimicking a solitary fibrous tumor (SFT).
Using BRAF and NRAS mutation analysis, it could be proven that
both lesions were melanoma metastases instead of SFT. Many
other soft tissue tumors can mimick melanoma or melanoma
metastasis, such as dermatofibrosarcoma protuberans, malignant
peripheral nerve sheath tumors (MPNST) (57), and sarcomas (48,
58–60).
AlthoughCDKN2Amutation frequency in sporadic melanomas
as well as consistency in melanoma metastasis are reported to be
low [reported CDKN2A mutation frequency in upto 25% of pri-
mary melanomas, 0–14% in melanoma metasases, with a 31%
consistency being reported between a primary and the metastasis
(61, 62)],CDKN2A mutation analysis can be an alternative way to
confirm a diagnosis of metastatic melanoma by showing a clonal
relationship between a primary melanoma and a metastasis [after
exclusion of a CDKN2A germline mutation (63)], as is illustrated
by a recent case from our own practice. A 36-year-old woman with
a history of a superficial spreading melanoma of the back 16 years
earlier, presented with a large lung mass, which was thought to be
a non-small cell lesion, probably squamous cell carcinoma based
on fine needle aspiration (EUS-FNA); melanoma markers HMB45
and MART were negative, while the squamous cell marker – p63 –
was weakly positive. Evaluation of the pneumonectomy specimen,
however, led to a differential diagnosis with metastatic melanoma,
since immunohistochemical stainings on the complete tumor now
available for histological evaluation showed in part features con-
sistent with melanocytic differentiation. Vimentin, tyrosinase, and
mitf were weakly positive; however, S100 and SOX10 were both
negative. Therefore, additional BRAF and CDKN2A mutation
analysis was performed. Identical mutations in both genes were
present in the primary cutaneous melanoma and the lung mass –
in absence of a germline CDKN2A mutation – confirming that the
lung mass was a late metastasis of the cutaneous melanoma. This
case is illustrated in Figure 6.
In a patient with a history of melanoma, it can occasionally
be difficult to differentiate between a second primary cutaneous
melanoma and a melanoma metastasis based on histomorphol-
ogy, especially when there is epidermotropism (64). If the first
melanoma was not a cutaneous melanoma, the problem can often
be solved by mutation analysis since different types of melanomas
have mutations in different genes of the MAPK pathway as men-
tioned in Table 1. If the primary melanoma was a cutaneous
melanoma, mutation analysis of NRAS and BRAF can be of help,
but since these mutations are hotspot mutations, it is of limited
use. Usage is additionally hampered by frequent occurrence of het-
erogeneity in melanoma with respect to NRAS and BRAF status,
leading to a substantial discordance in mutation status in these
genes in a primary compared to the metastases (61, 65).
CDKN2A mutation analysis can sometimes be helpful as we
have published before (66), and is illustrated by the case above, to
differentiate between a new primary and a melanoma metastasis.
The advantage of using CDKN2A mutations for clonality is that
CDKN2A mutations are unique mutations instead of hot spot
mutations. Although CDKN2A mutation frequency in sporadic
melanomas is low, CDKN2A mutation analysis to our opinion is
worth trying, as there is a substantial difference in the prognosis
between a second primary melanoma and a melanoma metastasis.
PART 2: MOLECULAR PATHOLOGY IN MELANOMA
TREATMENT
Metastatic melanoma treatment got a great impulse after the dis-
covery that the (hot spot) mutations in genes involved in the
MAPK pathway in melanoma, as well as in GNAQ and GNA11,
which proved targetable on the protein level by specific inhibitors.
GNAQ and GNA11 mutations are mainly present in uveal and pri-
mary brain melanomas, and combinations of MEK inhibitors with
either PI3K or mTOR inhibitors have shown efficacy in GNAQ-
and GNA11-mutant melanomas (67, 68). A simplified scheme of
the most important pathways involved in melanoma pathogenesis,
and points of action of specific inhibitors are depicted in Figure 1.
Melanomas from distinct locations have been shown to contain
different mutation types and frequencies (5, 11, 12). An overview
of the most frequent mutations in the distinct melanoma subtypes
and their frequencies, as well as the different therapeutic options,
are depicted in Table 1.
The most frequently tested genes at present in melanoma are
BRAF and NRAS, because these mutations are most prevalent in
melanoma, especially in those arising from the skin. Testing for
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FIGURE 6 | Case of a superficial spreading melanoma of the back with
lung metastasis 16 years later in a female patient. In (A), an overview of
the primary cutaneous melanoma showing centrally an asymmetrical
melanocytic lesion (HE, 25×). In (B), a more detailed picture showing clear
atypia with loss of maturation and ascension in the epidermis (HE, 100×). In
(C–E), the lung lesion at different magnifications [HE C 25×, (D,E) 100×]
showing a nodular proliferation of atypical partly plasmacytoid cells
resembling the primary cutaneous melanoma. Immunohistochemical S100
stain, however, was negative [(F) S100 immunostaining, 100×]. Internal and
external controls were positive. (G) Sequence plots demonstrated an
identical c.168_170delinsTG(p.(Arg58fs)) in the CDKN2A gene in both the skin
melanoma and the lung melanoma, which was absent in normal tissue of the
patient. This confirmed that the lung tumor was a metastasis of the previous
melanoma. The sequence plots are visualized as described under Figure 2.
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targeted treatment in melanoma should be guided by the local-
ization of the primary tumor. Nowadays, this issue becomes less
important because several molecular labs use platforms that detect
various regions from multiple genes within one test.
In case of molecular testing for targeted therapy in metastatic
melanoma, there are several important issues.
Molecular testing for therapy requires a close collaboration
between clinician, pathologist, and molecular biologist. Testing
for treatment should only be performed when targeted therapy
is considered as a therapeutic option. This can be judged best by
the clinician. In most cases, testing is only indicated in inoperable
stage 3 or stage 4 melanoma patients.
Tests need to be performed in an accredited molecular labora-
tory that guarantees that the laboratory techniques and processes
are performed standardized and yield high-quality results, which
imply that only validated tests are used.
The role of the pathologist is to confirm the diagnosis of
melanoma metastasis, to check representativity of the tumor tis-
sue to be examined, to indicate the area for macrodissection (if
needed) by the technician for DNA extraction, to indicate possible
tumor heterogeneity, and to estimate the neoplastic cell percentage
within the tested sample.
The knowledge and the expertise of trained molecular biol-
ogists are used to come to optimal test results and adequate
interpretation and reporting of molecular test results. The mol-
ecular report should contain information on the specific tissue
block tested, the percentage of neoplastic cells, the type of mol-
ecular test used, and the sensitivity of the test, the type of genes,
and exons or mutations thereof which are tested, and an accu-
rate description of the mutation present according to the Human
Genome Variation Society nomenclature. The molecular biologist,
together with the pathologist, is responsible for proper integra-
tion and interpretation of the molecular results in the pathology
report.
The molecular test is preferentially performed on a recent
metastasis. First, reason for this is confirmation of the diagno-
sis of melanoma metastasis. Second, there is considerable tumor
heterogeneity with a reported discrepancy by Colombino et al. of
7.5–29% in the BRAF andNRAS mutation status of the metastatic
melanoma when compared to the primary (61, 65). Concordance
seems dependent on the location of the metastases and is highest
for visceral (92.5%) and nodal metastases (91%), but relatively
low for brain (79%) and skin metastases (71%). Especially, in the
latter, testing should be performed on the metastasis.
Saint-Jean et al. (69) also reported discordant BRAF results.
They performed multiple tests in a subgroup of 74 patients: in
10/74 (13.5%) of these patients, BRAF status was discordant
between distinct samples of a patient. In two patients, the dis-
cordance was present between the primary and a metastasis. In six
patients, the discordance was present between two distinct metas-
tases. The authors state that without repeated testing, five patients
would unjustly have been excluded from treatment with the BRAF
inhibitor, vemurafenib. They advocate to test other samples in case
noBRAF mutation has been detected. We can agree with this espe-
cially in selected cases, when the primary location is likely to be
associated with a BRAF mutation and when no mutation in other
targetable genes (like NRAS or KIT ) have been identified.
A molecular test should be able to detect all relevant and tar-
getable mutations in a gene. The most frequently tested gene for
melanoma treatment at present is BRAF.
The most frequent BRAF mutation is a mononucleotide
point mutation in codon 600 (CTG) of exon 15, c.1799T>A
(p.(Val600Glu)), in which the valine (V) of codon 600 is replaced
by glutamine (E). This mutation is, therefore, known as the
BRAFV600E mutation and is present in about 70–75% of all BRAF-
mutated melanomas (11, 70, 71). In a recent study in which 1112
primary and metastatic melanomas from different locations were
analyzed for BRAF mutations (774 skin melanomas, 111 acral
melanomas, 26 mucosal melanomas, 23 uveal melanomas, 1 lep-
tomeningeal melanoma, and 177 metastases), 44.9% of the cases
harbored a BRAF mutation: in 75.4% of the cases, mutations were
BRAFV600E either deriving from the c.1799T>A or from a c.1799
1800delinsAA mutation. Of the remaining BRAFnon-V600E cases
(24.6%), the most frequently seen mutation was the BRAFV600K
(17.2%); BRAFV600R or BRAFV600D mutated cases were found
in low percentages (4.6%). BRAF exon 11 mutations were also
observed in a low percentage (0.4%).
There are several studies that have reported that all melanomas
with BRAF codon 600 mutations are sensitive to BRAF inhibitors,
such as vemurafenib (Zelboraf®, Roche Molecular Systems
Inc.) and dabrafenib (GSK2118436) (72, 73). This implicates
that a BRAF test needs to be able to detect not only the
BRAFc.1799T>A(p.(Val600Glu)/BRAFV600E mutation but the
other codon 600 mutations as well.
A test must be able to detect BRAF mutations that have been
reported to be insensitive to BRAF-inhibitor treatment, like the
kinase-dead mutation BRAFD594 (74, 75).
The molecular test for therapy should be performed within a
short turnaround time since mostly this kind of targeted therapy
will be given in rapidly progressive metastatic melanoma patients.
A turnaround time of 5 working days is feasible within our hands.
At present, we perform NGS-based mutation testing using
Ion Torrent Personal Genome Machine (IT-PGM) from Life
Technologies for analysis of gene-panels for diagnostic purposes.
At the moment, there is a tendency toward testing with NGS
methods for targeted treatment in diverse cancer types. The sen-
sitivity of NGS is higher than Sanger sequencing (detection of
2–10% versus 15–25% allele frequency). Moreover, the amount of
DNA that is needed for the analysis of gene panels is very low, only
10 ng for all amplicons for instance when using the IT-PGM from
Life Technologies versus 10 ng needed per amplicon for Sanger
sequencing.
The turnaround time and costs of NGS methods can be com-
petitive with respect to low throughput technologies in centers
that have sufficient numbers of samples.
For diagnostic requests in melanoma in our department, a
custom-designed gene panel for amplicon-sequencing of BRAF
(NM_004333.4) exon 15, NRAS (NM_002524.4) exon 2 and 3,
HRAS (NM_005343.2) exon 2 and 3,AKT1 (NM_005163.2) exon
3, GNAQ (NM_002072.2) exon 4 and 5, GNA11 (NM_002067.2)
exon 4 and 5, KIT NM_000222.2) exon 8, 9, 11, 13, and 14, and
PDGFRA (NM_006206.4) exon 12, 14, and 18 is performed.
The use of small, dedicated gene panels and efficient loading of
the chips for IT-PGM also significantly reduce costs per case.
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The major benefit of (targeted) NGS is that it uncovers all kinds
of mutations in selected genomic regions instead of only mutations
at predefined positions.
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